substance-p--arg(1)-pro(2)-trp(7-9)-leu(11)- and Lung-Neoplasms

substance-p--arg(1)-pro(2)-trp(7-9)-leu(11)- has been researched along with Lung-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for substance-p--arg(1)-pro(2)-trp(7-9)-leu(11)- and Lung-Neoplasms

ArticleYear
[D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P inhibits the growth of human small cell lung cancer xenografts in vivo.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:10

    We report the effect of substance P analogue, [D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P (D-Phe5SP), on the growth of human small cell lung cancer (SCLC) xenografts HC12 and ICR-SC112. Daily intraperitoneal (ip) administration (500 micrograms/day for 3 weeks) had no effect on HC12 growth rate. When administered by continuous 14-day subcutaneous (sc) infusion by osmotic minipump implanted adjacent to the tumour, D-Phe5SP 2.1 micrograms/day, caused significant inhibition (P < 0.05) of the growth of HC12 and ICR-SC112 on day 7 and day 14 compared with phosphate buffered saline (PBS)-treated controls. HC12 and ICR-SC112 tumour volume remained at 53-67% of control for 14-21 days postinfusion. D-Phe5SP 1 mg/day did not inhibit tumour growth, but dense fibrous capsules developed at the minipump outlet. Animals treated by sc infusion (but not ip) of PBS or D-Phe5SP failed to gain weight, and some groups lost weight. D-Phe5SP-treated animals had lower white blood counts than controls (not significant). These data suggest a potential clinical role for D-Phe5SP in the treatment of SCLC.

    Topics: Animals; Carcinoma, Small Cell; Drug Screening Assays, Antitumor; Growth Inhibitors; Humans; Injections, Subcutaneous; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Recombinant Proteins; Substance P; Time Factors; Transplantation, Heterologous

1993
A neuropeptide antagonist that inhibits the growth of small cell lung cancer in vitro.
    Cancer research, 1990, Jul-01, Volume: 50, Issue:13

    In the search for novel antiproliferative agents for small cell lung cancer (SCLC), we found the neuropeptide antagonist [Arg6, D-Trp7,9,MePhe8]substance P(6-11) to be effective in vitro. In murine Swiss 3T3 cells [Arg6,D-Trp7,9,MePhe8]substance P(6-11) was identified as a potent inhibitor of vasopressin-stimulated DNA synthesis which also blocks [3H]vasopressin binding to specific cell-surface receptors. It was a less potent antagonist of gastrin-releasing peptide and bradykinin in these cells but did not block the effects of other mitogens. In SCLC cell lines, [Arg6,D-Trp7,9,MePhe8]substance P(6-11) inhibited colony-formation in soft agarose and growth in liquid culture in a dose-dependent manner. It also blocked receptor-mediated Ca2+ mobilization induced by vasopressin, bradykinin, cholecystokinin, galanin, gastrin-releasing peptide, and neurotensin. We suggest that broad-spectrum neuropeptide antagonists can block multiple autocrine and paracrine growth loops in SCLC and could be useful therapeutic agents.

    Topics: Animals; Bradykinin; Calcium; Carcinoma, Small Cell; Cell Division; Cells, Cultured; DNA, Neoplasm; Drug Screening Assays, Antitumor; Gastrin-Releasing Peptide; Humans; Lung Neoplasms; Mice; Peptide Fragments; Peptides; Recombinant Proteins; Substance P; Tumor Cells, Cultured; Vasopressins

1990